Compugen Secures Non-Dilutive Funding for Rilvegostomig and Advances GS-0321.

Compugen has secured non-dilutive funding for its Rilvegostomig program and has made progress with GS-0321. The funding will support the development of Rilvegostomig, a potential best-in-class anti-PVRIG drug, which targets patients with PSOC. GS-0321 is a potential first-in-class anti-PSOC antibody drug candidate.